The early health economic assessments provided insight in the potential cost-effectiveness of an innovation in its intended context, and the associated uncertainty. None of the assessments resulted in a firm 'no-go' recommendation, but recommendations could be provided on further research and development in order to maximize value for money.
No takes yet. Share an insight, caveat, or question.
Grutters et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: